Biogen (BIIB) Selling, General & Administrative (2009 - 2026)
Biogen (BIIB) Selling, General & Administrative (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 6.43 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.63 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 2.90 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 3.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 5.65 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.75 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 1.92 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 3.41 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -2.95 Bn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | 709.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 709.70 Mn |
| Mar 31, 2026 | 607.30 Mn |
| Dec 31, 2025 | 682.50 Mn |
| Sep 30, 2025 | 594.80 Mn |
| Jun 30, 2025 | 583.80 Mn |
| Mar 31, 2025 | 572.50 Mn |
| Dec 31, 2024 | 680.00 Mn |
| Sep 30, 2024 | 588.40 Mn |
| Jun 30, 2024 | 553.80 Mn |
| Mar 31, 2024 | 581.50 Mn |
| Dec 31, 2023 | 608.50 Mn |
| Sep 30, 2023 | 788.20 Mn |
| Jun 30, 2023 | 548.00 Mn |
| Mar 31, 2023 | 605.00 Mn |
| Dec 31, 2022 | 632.80 Mn |
| Sep 30, 2022 | 563.30 Mn |
| Jun 30, 2022 | 572.60 Mn |
| Mar 31, 2022 | 634.90 Mn |
| Dec 31, 2021 | 787.90 Mn |
| Sep 30, 2021 | 654.10 Mn |